Outsourced Pharma White Papers

  1. Random And Semi-Targeted Integration In Cell Line Development 8/5/2025

    While semi-targeted approaches may offer precision, uncover how they may fall short in overall efficiency and productivity, especially in late-stage manufacturing.

  2. Aseptic Process Design And Simulation Under Annex 1 Guidelines 1/9/2026

    Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.

  3. BioServices: Advanced Solutions For Cell And Gene Therapy Material Management 6/28/2024

    See how supply chain solutions like BioServices can help companies mitigate risk to their overall supply chain while saving valuable capital for the research of their lifesaving therapies.

  4. Quality By Design (QbD) For Biologics From A CDMO Perspective 2/18/2025

    Adopt QbD principles in your biologics development and manufacturing process to ensure consistent product quality, mitigate risks, and align with patient safety and commercial success goals.

  5. Navigating CMC Regulation For Plasmid DNA In Gene Therapy 5/28/2025

    Explore how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.

  6. Email Etiquette That Actually Saves Time for Pharma & Biotech 5/12/2026

    Smarter email habits cut wasted time, reduce inbox noise, and improve collaboration. Clear subject lines, careful recipients, and purposeful tool use keep teams focused on meaningful work.

  7. Harnessing Chemistry For Scalable Manufacture Of Lipids Used In mRNA Delivery 1/28/2025

    Discover how scalable lipid nanoparticle (LNP) technology is revolutionizing mRNA-based therapies and shaping the future of treatment innovation.

  8. A Risk-Based Approach To Plasmid DNA And mRNA Process Development 9/23/2025

    Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.

  9. Precision By Design: Drug Innovation Through Structure-Based Drug Design (SBDD) 5/6/2026

    Leverage structure-based drug design to gain deeper molecular insights, prioritize high-potential candidates, and accelerate your path from discovery to clinic.

  10. Smart Scaling For Cell And Gene Therapies 2/5/2026

    To meet patient demand, advanced therapy manufacturing processes must be commercial ready. CGT sponsors can mitigate risk and protect viability by partnering with a CDMO that prioritizes scalability.